Medico Remedies Q4 FY26 Results: PAT Rs 6 Cr

Medico Remedies Q4 FY26 results were declared on May 21, 2026. The company reported PAT of Rs 6 crore for the quarter ended March 31, 2026, up 50.0% YoY compared to Rs 4 crore in Q4 FY25. Revenue from operations stood at Rs 57 crore, up 39.0% YoY. Results are on a Standalone basis. Medico Remedies is a Pharmaceuticals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Medico Remedies Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	57	41	+39.0%
Gross Profit	Rs 6 crore	6	+0.0%
Net Profit	6	4	+50.0%
Basis	Standalone

Note: Medico Remedies Q4 FY26 results declared May 21, 2026. Verify from BSE/NSE audited filings before investment decisions.

Medico Remedies Q4 FY26 Performance Analysis

The Medico Remedies Q4 FY26 results reflect the company’s operational performance in the January to March 2026 quarter. The company delivered steady performance in line with sector trends. Medico Remedies operates in the Pharmaceuticals sector, which benefited from India’s GDP growth above 6.5% in FY26.

Revenue grew 39% YoY to Rs 57 crore, driven by strong demand and business expansion.

Screen the best stocks on the Univest Screener.

Key Factors Driving Medico Remedies Q4 FY26 Results

Revenue and Business Performance

Medico Remedies Q4 FY26 revenue of Rs 57 crore was up 39.0% YoY. The strong revenue growth reflects market share gains, capacity expansion, and healthy demand conditions.

Profitability and Margins

The business PAT of Rs 6 crore is up 50.0% YoY. The strong PAT growth demonstrates improving operational leverage and cost discipline.

India Macro Backdrop

The January to March 2026 quarter benefited from India’s GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore for FY27, and resilient domestic consumption. RBI’s accommodative stance supported credit and demand conditions. The Pharmaceuticals sector saw strong tailwinds during this period.

FY27 Outlook

Following the firm results, management commentary on FY27 revenue guidance, margin expansion roadmap, and capital allocation will be key investor watchpoints. The Pharmaceuticals sector continues to benefit from India’s long-term structural growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.